COMPLEMENT 3 GLOMERULOPATHY (C3G)

Clinical trials for COMPLEMENT 3 GLOMERULOPATHY (C3G) explained in plain language.

Never miss a new study

Get alerted when new COMPLEMENT 3 GLOMERULOPATHY (C3G) trials appear

Sign up with your email to follow new studies for COMPLEMENT 3 GLOMERULOPATHY (C3G), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1 Completed 1

Breakthrough injection shows promise for devastating kidney conditions

Disease control Completed

This Phase 3 study tested whether pegcetacoplan injections could help people with rare kidney diseases called C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN). The trial involved 124 participants who received either the actual drug or p…

Matched conditions: COMPLEMENT 3 GLOMERULOPATHY (C3G)

Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control

Last updated Mar 27, 2026 12:41 UTC

COMPLEMENT 3 GLOMERULOPATHY (C3G)

Get alerted when new COMPLEMENT 3 GLOMERULOPATHY (C3G) trials appear

Breakthrough injection shows promise for devastating kidney conditions